C. Robert a, ⁎, K. Flaherty b, P. Hersey c, P. Nathan d, C. Garbe e, M. Milhem f, L. Demidov g, J. Hassel h, P. Rutkowski i, P. Mohr j, R. Dummer k, U. Trefzer l, J. Larkin m, J. Utikal n, M. Casey o, L. Sherman o, W. Crist o, F. Wu o, K. Patel o, D. Schadendorf p
a Dermatologie, Institut Gustave-Roussy, Villejuif, France
b Oncology, Massachusetts General Hospital, Boston, États-Unis
c Melanoma Institute Australia, University of Sydney, Sydney, Australie
d Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, Royaume-Uni
e Dermatology, University Medical Center, Tuebingen, Allemagne
f Oncology, Department of Internal Medicine, University of Iowa, Iowa City, États-Unis
g Oncology, N.N.Blokhin Russian Cancer Research Center, Moscou, Fédération de Russie
h Dermatologie, Department of Dermatology, University Hospital Heidelberg, Heidelberg, Allemagne
i Department of Soft Tissue/Bone Sarcoma and Melanoma, Department of Soft Tissue/Bone Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Varsovie, Pologne
j Dermatology, Elbekliniken, Buxtehude, Allemagne
k Dermatology, University of Zurich, Zurich, Suisse
l Dermatologie, Charité, Berlin, Allemagne
m Medecine, Royal Marsden Hospital, Londres, Royaume-Uni
n Skin Cancer Unit, German Cancer Research Center, Heidelberg, Allemagne
o GlaxoSmithKline, Philadelphie, États-Unis
p Dermatologie, Hôpital Essen, Essen, Allemagne